KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $111.2 million.

  • Halozyme Therapeutics' Accumulated Expenses rose 15.31% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year increase of 15.31%. This contributed to the annual value of $128.9 million for FY2024, which is 27.98% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Accumulated Expenses is $111.2 million, which was down 3.81% from $115.6 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Accumulated Expenses high stood at $130.3 million for Q1 2025, and its period low was $16.1 million during Q1 2021.
  • Over the past 3 years, Halozyme Therapeutics' median Accumulated Expenses value was $111.2 million (recorded in 2025), while the average stood at $109.1 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Accumulated Expenses tumbled by 39.96% in 2021, and later surged by 336.34% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Accumulated Expenses (Quarterly) stood at $24.4 million in 2021, then soared by 308.17% to $99.8 million in 2022, then increased by 0.92% to $100.7 million in 2023, then climbed by 27.98% to $128.9 million in 2024, then rose by 15.31% to $111.2 million in 2025.
  • Its last three reported values are $111.2 million in Q3 2025, $115.6 million for Q2 2025, and $130.3 million during Q1 2025.